Semaglutide API prices are falling sharply as global demand for weight-loss drugs like Ozempic and Wegovy drives rapid manufacturing expansion. With patents set to expire in key markets and Indian companies rolling out lower-priced generics, analysts expect additional price softening. The shift could widen access to these GLP-1 therapies for patients in the months ahead.
India’s weight-loss drug market is rapidly shifting as generic semaglutide becomes available after Novo Nordisk’s patent loss. The cheaper alternatives are already pressuring Eli Lilly’s sales while unlocking a surge in demand. With multiple Indian drugmakers racing to launch affordable options, the country’s obesity-treatment landscape is entering a new, more price-accessible phase.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Mounjaro sales are sliding across India as Novo Nordisk drives a price war for Ozempic and Wegovy and cheaper semaglutide generics gain traction. Eli Lilly says it’s seeing increased competition but remains confident in Mounjaro’s differentiated benefits for users. The shift highlights how rapidly GLP-1 therapy markets are being reshaped by pricing pressure.
Dr Reddy’s has received regulatory approval in India to roll out its generic oral semaglutide. The approval follows a head to head comparative study in India that found the formulation non inferior to Novo Nordisk’s Rybelsus. The company says this clinical evidence helped it secure approval under India’s biosimilar regulatory pathway.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
